AWM Investment Company Inc. Grows Stock Holdings in OrthoPediatrics Corp. (NASDAQ:KIDS)

AWM Investment Company Inc. increased its stake in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 14.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 516,794 shares of the company's stock after buying an additional 66,779 shares during the quarter. AWM Investment Company Inc. owned about 2.13% of OrthoPediatrics worth $11,979,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Invesco Ltd. lifted its holdings in shares of OrthoPediatrics by 3.0% during the 4th quarter. Invesco Ltd. now owns 16,363 shares of the company's stock worth $379,000 after acquiring an additional 469 shares during the period. Northern Trust Corp raised its position in OrthoPediatrics by 0.3% during the fourth quarter. Northern Trust Corp now owns 193,798 shares of the company's stock valued at $4,492,000 after purchasing an additional 644 shares in the last quarter. Rhumbline Advisers lifted its stake in OrthoPediatrics by 4.1% during the fourth quarter. Rhumbline Advisers now owns 26,411 shares of the company's stock worth $612,000 after purchasing an additional 1,042 shares during the last quarter. R Squared Ltd bought a new position in OrthoPediatrics in the fourth quarter valued at about $48,000. Finally, Bank of New York Mellon Corp raised its stake in shares of OrthoPediatrics by 3.8% during the fourth quarter. Bank of New York Mellon Corp now owns 57,710 shares of the company's stock valued at $1,338,000 after acquiring an additional 2,099 shares during the last quarter. Institutional investors own 69.05% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on KIDS shares. Lake Street Capital began coverage on shares of OrthoPediatrics in a research report on Monday, April 7th. They set a "buy" rating and a $37.00 target price for the company. Truist Financial decreased their price target on shares of OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Piper Sandler dropped their price objective on shares of OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. Stifel Nicolaus reduced their target price on OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, March 5th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $42.00 target price on shares of OrthoPediatrics in a research report on Thursday, May 8th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $35.83.

OrthoPediatrics Stock Performance

OrthoPediatrics stock traded down $0.32 during mid-day trading on Monday, reaching $20.83. The company's stock had a trading volume of 72,124 shares, compared to its average volume of 196,893. The firm's fifty day moving average price is $22.54 and its two-hundred day moving average price is $23.71. OrthoPediatrics Corp. has a 12-month low of $20.25 and a 12-month high of $35.99. The company has a market capitalization of $505.90 million, a P/E ratio of -16.93 and a beta of 1.09. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.13). The business had revenue of $52.41 million during the quarter, compared to the consensus estimate of $51.68 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. Sell-side analysts predict that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

Insider Buying and Selling at OrthoPediatrics

In other news, CEO David R. Bailey sold 6,620 shares of the company's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $164,573.20. Following the transaction, the chief executive officer now directly owns 319,155 shares of the company's stock, valued at $7,934,193.30. This represents a 2.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Fred Hite sold 6,443 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $160,172.98. Following the transaction, the chief financial officer now directly owns 207,989 shares in the company, valued at $5,170,606.54. The trade was a 3.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,732 shares of company stock valued at $589,978. 32.70% of the stock is currently owned by company insiders.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.